Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genetic model of MS severity predicts future accumalation of disability

ABSTRACT: Genetic model of MS severity predicts future accumalation of disability

PROVIDER: PRJNA545548 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Genetic model of MS severity predicts future accumalation of disability

Project description:Genetic model of MS severity predicts future accumalation of disability

| PRJNA545549 | ENA

Genetic model of MS severity predicts future accumulation of disability.

Project description: Not available

| S-EPMC6898742 | biostudies-literature

A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity

Project description:A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity These data support the publication titled "A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity" Copyright (c) 2005 by Iconix Pharmaceuticals, Inc. Guidelines for commercial use: http://www.iconixbiosciences.com/guidelineCommUse.pdf replicated drug treatments with controls

2005-11-30 | E-GEOD-3210 | biostudies-arrayexpress

Genetic Model of MS Severity

Project description:The goal of "Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the CNS" is to define the pathophysiological mechanisms underlying the development of disability in immune-mediated disorders of the central nervous system (CNS) and to distinguish these from physiological (and often beneficial) responses of the human immune system to CNS injury. The long-term objective of the trial is to acquire knowledge that would allow us to therapeutically inhibit the pathogenic mechanisms and enhance repair mechanisms in immune-mediated CNS diseases, thereby minimizing the extent of CNS tissue damage and promoting recovery. To date, 460 patients with a confirmed diagnosis of multiple sclerosis (MS) have been enrolled into the natural history clinical trial. In addition to standardized clinical, functional, neuroimaging and molecular/immunological data, blood samples were also collected for genetic research. However, only 299 study participants with confirmed MS currently have whole genome sequencing data available. In addition to the genome-wide data available for the 299 MS patients, this dbGaP submission provides demographic and phenotypic information for each subject collected at various points throughout the trial. We include race and family history of MS collected at the baseline visit as well as age and measures of disease severity collected at the most recent visit. As these data were randomized into discovery and validation cohorts, we also indicate the assigned group in the phenotypic data. It is hoped that these data may be applied to the development of clinically-useful tools such as diagnostic tests and new, sensitive scales of neurological disability, disease severity and CNS tissue destruction.

| phs001833 | dbGaP

A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity

2005-12-01 | GSE3210 | GEO

Antecedent enhancer activity predicts future susceptibility to seizures in mice

Project description:Antecedent enhancer activity predicts future susceptibility to seizures in mice

| PRJNA1307581 | ENA

New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability.

Project description: Not available

| S-EPMC5686060 | biostudies-literature

Baseline assessment of circulating microRNAs near diagnosis of type 1 diabetes predicts future stimulated insulin secretion

Project description:We investigated whether circulating microRNAs (miRNAs) are associated with residual insulin secretion at diagnosis and predict the severity of its future decline. We studied 53 newly diagnosed subjects enrolled in placebo groups of TrialNet clinical trials. We measured serum levels of 2,083 miRNAs using RNAseq technology, in fasting samples from the baseline visit (<100 days from diagnosis), during which residual insulin secretion was measured with a mixed meal tolerance test (MMTT). Area under the curve (AUC) C-peptide and peak C-peptide were stratified by quartiles of expression of 31 miRNAs. After adjustment for baseline C-peptide, age, BMI and sex, baseline levels of miR-3187-3p, miR-4302, and the miRNA combination of miR-3187-3p/miR-103a-3p predicted differences in MMTT C-peptide AUC/peak levels at the 12-month visit; the combination miR-3187-3p/miR-4723-5p predicted proportions of subjects above/below the 200 pmol/L clinical trial eligibility threshold at the 12-month visit. Thus, miRNA assessment at baseline identifies associations with C-peptide and stratifies subjects for future severity of C-peptide loss after 1 year. We suggest that miRNAs may be useful in predicting future C-peptide decline for improved subject stratification in clinical trials.

2020-09-01 | GSE157177 | GEO

A non-synonymous SNP in SIRT6 predicts neurological severity in Friedreich ataxia

Project description:A non-synonymous SNP in SIRT6 predicts neurological severity in Friedreich ataxia

| PRJNA827169 | ENA

Glomus sp. MS strain:MS

Project description:Glomus sp. MS strain:MS Genome sequencing

| PRJNA210520 | ENA